10 months ago
SRPT
AnalystsDanielle BrillDanielle Brill's Stock Forecasts
AnalystsDanielle Brill
Analyst Ranking
Bottom 7%
#4668 out of 4981 analysts
Average Return
-4.43%
Win Rate
44%31 out of 71
Risk vs Reward
Poor
Good
Danielle Brill's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Uniqure NvQURE | +198.52% | $5.42 | $16.18 | 2024-10-10 - 2025-08-15 | Buy |
Sage Therapeutics IncSAGE | +149.76% | $70.20 | $175.33 | 2017-05-16 - 2018-05-16 | Buy |
Argenx SeARGX | +76.16% | $354.13 | $623.82 | 2023-12-21 - 2024-12-20 | Strong Buy |
Palvella Therapeutics IncPVLA | +52.58% | $31.00 | $47.30 | 2025-07-21 - 2025-08-15 | Strong Buy |
Harmony Biosciences Holdings IncHRMY | +48.54% | $23.90 | $35.50 | 2023-10-16 - 2024-10-15 | Buy |
Danielle Brill Analyst Color
Get additional color on Danielle Brill's coverage of popular stocks
Danielle Brill's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Disc Medicine IncIRON | 5 | Strong Buy | $86.00 | +43.67% | Initiates Coverage On | a month ago |
Alnylam Pharmaceuticals IncALNY | 1 | Strong Buy | $385.00 | -14.24% | Initiates Coverage On | a month ago |
Harmony Biosciences Holdings IncHRMY | 8 | Strong Buy | $48.00 | +30.19% | Initiates Coverage On | a month ago |
Palvella Therapeutics IncPVLA | 1 | Strong Buy | $56.00 | +18.39% | Initiates Coverage On | a month ago |
Tectonic Therapeutic IncTECX | 2 | Strong Buy | $64.00 | +172.22% | Initiates Coverage On | a month ago |
Neurocrine Biosciences IncNBIX | 6 | Strong Buy | $163.00 | +22.65% | Initiates Coverage On | a month ago |
Bridgebio Pharma IncBBIO | 1 | Strong Buy | $66.00 | +28.60% | Initiates Coverage On | a month ago |
Centessa Pharmaceuticals PLCCNTA | 1 | Strong Buy | $30.00 | +66.20% | Initiates Coverage On | a month ago |
Jefferson Capital IncJCAP | 1 | Strong Buy | $24.00 | +28.82% | Initiates Coverage On | a month ago |
Uniqure NvQURE | 6 | Strong Buy | $52.00 | +221.38% | Upgrades | 8 months ago |
Biomarin Pharmaceutical IncBMRN | 1 | Buy | $79.00 | +37.30% | Reinstates | 10 months ago |
Regenxbio IncRGNX | 1 | Buy | $18.00 | +104.08% | Reinstates | 10 months ago |
Immunovant IncIMVT | 4 | Buy | $36.00 | +136.53% | Reinstates | 10 months ago |
Sarepta Therapeutics IncSRPT | 2 | Buy | $150.00 | +587.76% | Reinstates | 10 months ago |
Argenx SeARGX | 7 | Strong Buy | $605.00 | -7.47% | Reinstates | 10 months ago |
Xenon Pharmaceuticals IncXENE | 2 | Buy | $50.00 | +30.79% | Reinstates | 10 months ago |
Agios Pharmaceuticals IncAGIO | 2 | Buy | $51.00 | +37.80% | Reinstates | 10 months ago |
Biogen IncBIIB | 1 | Buy | $283.00 | N/A | Upgrades | 2 years ago |
Passage Bio IncPASG | 5 | Buy | $100.00 | N/A | Maintains | 2 years ago |
Ptc Therapeutics IncPTCT | 6 | Buy | $55.00 | N/A | Maintains | 2 years ago |
Fibrogen IncFGEN | 2 | Buy | $875.00 | N/A | Upgrades | 3 years ago |
Acceleron Pharma IncXLRN | 2 | Hold | N/A | N/A | Downgrades | 4 years ago |
Vertex Pharmaceuticals IncVRTX | 1 | Hold | N/A | N/A | Initiates Coverage On | 4 years ago |
Acadia Pharmaceuticals IncACAD | 2 | Buy | $35.00 | N/A | Downgrades | 4 years ago |
Global Blood Therapeutics IncGBT | 4 | Hold | $50.00 | N/A | Downgrades | 5 years ago |
Gw Pharmaceuticals PLCGWPH | 1 | Hold | N/A | N/A | Initiates Coverage On | 5 years ago |
Zogenix IncZGNX | 1 | Hold | N/A | N/A | Initiates Coverage On | 5 years ago |
Alder Biopharmaceuticals IncALDR | 2 | Buy | $28.00 | N/A | Assumes | 7 years ago |
Sage Therapeutics IncSAGE | 1 | Buy | $82.00 | N/A | Initiates Coverage On | 8 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.